Risk Factors Update Summary
- Halted clinical development may result in delays or elimination of certain plans, impacting funding.
- Resuming clinical development is crucial for obtaining additional funding and commercializing product candidates.
- Heavy dependence on lead product candidate avasopasem, not yet approved, poses significant risks.
- Reliance on third parties for clinical trials increases the risk of incomplete data and delays.
- Lack of approved products may hinder revenue generation and commercialization efforts.
- Limited influence over third-party performance may impact development and commercialization efforts.
- Market opportunities uncertainty and narrower approvals could adversely affect revenue and profitability.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1563577&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.